Sequence: (RXRRBR)2XB
morpholino oligonucleotide (PMO)
| Experiment Id | EXP002163 |
|---|---|
| Paper | A peptide conjugate enables systemic injection of the morpholino inducer and more durable induction |
| Peptide | B-M8 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | intramuscular-dependent dosing (0.5 mg/kg i.m.; 10 mg/kg i.v.) |
| Mixing Ratio | covalent peptide–PMO conjugate |
| Formulation Format | CPP–PMO conjugate |
| Formulation Components | B-M8 |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c mice |
| Administration Route | intramuscular |
| Output Type | AAV reporter gene induction (bioluminescence) |
| Output Value | ≈135-fold induction |
| Output Units | |
| Output Notes | CPP-conjugated PMO improves induction duration compared to v-M8 but limited systemic efficacy. |
| Toxicity Notes | No toxicity reported |
| Curation Notes |